In:
Journal of Labelled Compounds and Radiopharmaceuticals, Wiley, Vol. 58, No. 7 ( 2015-06-15), p. 308-312
Abstract:
Nintedanib is a novel triple angiokinase inhibitor that inhibits three growth factors simultaneously. Deuterated derivatives of nintedanib at certain metabolically active sites were prepared and evaluated in vitro and in vivo . In particular, deuterated compound SKLB‐C2202 had significantly improved pharmacokinetic properties compared with nintedanib. These efforts lay the foundation for further investigating the druggability of SKLB‐C2202.
Type of Medium:
Online Resource
ISSN:
0362-4803
,
1099-1344
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
1491841-9
SSG:
15,3
Permalink